ProQR Therapeutics N.V.

BMV:PRQR N Stock Report

Market Cap: Mex$7.2b

ProQR Therapeutics Past Earnings Performance

Past criteria checks 0/6

ProQR Therapeutics has been growing earnings at an average annual rate of 9.9%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 51.2% per year.

Key information

9.9%

Earnings growth rate

23.9%

EPS growth rate

Biotechs Industry Growth12.9%
Revenue growth rate51.2%
Return on equity-95.8%
Net Margin-130.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How ProQR Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BMV:PRQR N Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2418-241433
30 Jun 2416-221530
31 Mar 2411-271628
31 Dec 237-281625
30 Sep 235-361428
30 Jun 234-541738
31 Mar 234-591844
31 Dec 224-641951
30 Sep 224-692153
30 Jun 224-612048
31 Mar 223-631947
31 Dec 212-611742
30 Sep 212-571638
30 Jun 212-551435
31 Mar 211-431334
31 Dec 201-471438
30 Sep 201-521444
30 Jun 201-511446
31 Mar 202-581447
31 Dec 192-561346
30 Sep 193-511442
30 Jun 195-451337
31 Mar 196-401334
31 Dec 186-371330
30 Sep 184-351128
30 Jun 182-401129
31 Mar 181-441131
31 Dec 171-441131
30 Sep 171-411031
30 Jun 171-41932
31 Mar 171-39933
31 Dec 162-39932
30 Sep 163-36930
30 Jun 163-33928
31 Mar 163-31825
31 Dec 153-21723
30 Sep 153-17720
30 Jun 151-14817
31 Mar 151-10814
31 Dec 140-12710
30 Sep 140-1258
30 Jun 140-936
31 Mar 140-514
31 Dec 130-313

Quality Earnings: PRQR N is currently unprofitable.

Growing Profit Margin: PRQR N is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PRQR N is unprofitable, but has reduced losses over the past 5 years at a rate of 9.9% per year.

Accelerating Growth: Unable to compare PRQR N's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRQR N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).


Return on Equity

High ROE: PRQR N has a negative Return on Equity (-95.83%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/10 17:48
End of Day Share Price 2024/09/12 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ProQR Therapeutics N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffB. Riley Wealth
Eliana MerleCantor Fitzgerald & Co.
Steven SeedhouseCGS International